Compare Biogen Inc (BIIB) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Celsius Holdings, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Celsius Holdings, Inc. trades at $27.66 (market cap $7.11B). The key difference: Biogen Inc is far larger — about 4.2× Celsius Holdings, Inc.'s market cap, and Biogen Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| BIIB | CELH | |
|---|---|---|
Market Cap | $30.13B | $7.11B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $64.86 |
52-Week Low | $128.93 | $23.77 |
Enterprise Value | $37.20B | $8.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
CELH trades at $27.48, up 0.99% on the day, but remains under bearish technical pressure with key resistance at $29. The company reported Q2 2026 earnings that missed expectations, with revenue growth slowing to 11% year-over-year as core brand sales weakened, though Alani Nu and Rockstar acquisitions provided some offset. Net cash flow was negative $350.20 million in 2025 due to significant investing activities.
Outlook is mixed; strong analyst buy consensus (95.65%) and a $44.08 price target suggest long-term confidence in growth via PepsiCo partnership, but near-term risks include execution challenges, margin pressure, and ongoing investigations into management disclosures. The stock's high P/E of 122.13 reflects growth expectations that must materialize to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
